More articles from Interpreting Key Trials

  • Interpreting EVERDAC: Deferring arterial cannulation in critically ill patients with shock

    Adrienne K. Ho, MBBS, MSc
    • Cleveland Clinic Journal of Medicine October 2026, 93 (10) 597-602;
    • DOI: https://doi.org/10.3949/ccjm.93a.25108

    • Results of the EVERDAC trial challenge the strategy of reflexively placing an arterial line when a patient is admitted to the intensive care unit.

  • FINEARTS-HF: Improving outcomes in heart failure with preserved or mildly reduced ejection fraction

    Salman Salahuddin, MD, DM, MRCP(UK)
    • Cleveland Clinic Journal of Medicine May 2026, 93 (5) 273-277;
    • DOI: https://doi.org/10.3949/ccjm.93a.25081

    • FINEARTS-HF established finerenone as an effective medical therapy to reduce hospitalizations for heart failure in patients with HFpEF or HFmrEF.

  • Interpreting the DIGIT-HF trial: Time for a new look at digitalis?

    Enmanuel A. Leiva-Murillo, MD, Oriol Ventosa-Blázquez, MD and Eduard Solé-González, MD, PhD
    • Cleveland Clinic Journal of Medicine April 2026, 93 (4) 218-226;
    • DOI: https://doi.org/10.3949/ccjm.93a.25098

    • Digitoxin reduced the risk of death or first hospitalization for heart failure in patients with symptomatic heart failure with reduced ejection fraction who were already being treated with guideline-directed medical therapy.

  • Insights from the LAAOS III trial of left atrial appendage occlusion to prevent stroke in atrial fibrillation

    Anže Djordjević, MD, PhD and Edward Soltesz, MD, MPH
    • Cleveland Clinic Journal of Medicine July 2025, 92 (7) 415-419;
    • DOI: https://doi.org/10.3949/ccjm.92a.25001

    • Left atrial appendage occlusion added to routine cardiac surgery reduced the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation and high stroke risk, but questions remain.

  • Update in perioperative cardiac medicine 2021

    Steven L. Cohn, MD, MACP, SFHM
    • Cleveland Clinic Journal of Medicine April 2021, 88 (4) 216-220;
    • DOI: https://doi.org/10.3949/ccjm.88a.21014

    • New light on preoperative assessment and on the need for anticoagulation.

  • The role of ISCHEMIA in stable ischemic heart disease

    Nikolaos Spilias, MD, Benjamin Zorach, MD, Kara Denby, MD and Stephen Ellis, MD
    • Cleveland Clinic Journal of Medicine July 2020, 87 (7) 401-409;
    • DOI: https://doi.org/10.3949/ccjm.87a.20033

    • Decisions regarding treatment of stable ischemic heart disease must remain individualized.

  • Renal denervation: What happened, and why?

    Mehdi H. Shishehbor, DO, MPH, PhD, Tarek A. Hammad, MD and George Thomas, MD, MPH
    • Cleveland Clinic Journal of Medicine September 2017, 84 (9) 681-686;
    • DOI: https://doi.org/10.3949/ccjm.84a.14129

    • Despite promising initial results, this treatment failed in its largest trial to date. Is it dead? Can it be revived?

  • Interpreting SPRINT: How low should you go?

    George Thomas, MD, FACP, FASN, Joseph V. Nally, MD and Marc A. Pohl, MD
    • Cleveland Clinic Journal of Medicine March 2016, 83 (3) 187-195;
    • DOI: https://doi.org/10.3949/ccjm.83a.15175

    • In treating hypertension, lower systolic pressure is better than higher—but with caveats.

  • TOC Icon

    A new class of drugs for systolic heart failure: The PARADIGM-HF study

    Marwa A. Sabe, MD, MPH, Miriam S. Jacob, MD and David O. Taylor, MD
    • Cleveland Clinic Journal of Medicine October 2015, 82 (10) 693-701;
    • DOI: https://doi.org/10.3949/ccjm.82a.14163

    • Valsartan-sacubitril is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.

  • The METEOR trial: No rush to repair a torn meniscus

    Yong Gil Hwang, MD and C. Kent Kwoh, MD
    • Cleveland Clinic Journal of Medicine April 2014, 81 (4) 226-232;
    • DOI: https://doi.org/10.3949/ccjm.81a.13075

    • Many patients who have osteoarthritis of the knee and a torn meniscus can defer surgery and undergo physical therapy instead.

Previous
Next